Acadia Healthcare Company Earnings Call Transcripts
Fiscal Year 2026
-
Revenue and Adjusted EBITDA exceeded guidance in Q1 2026, driven by strong acute and RTC performance. Full-year Adjusted EBITDA and EPS guidance were raised, while operational improvements and leadership changes support continued growth.
-
Leadership changes have energized operations, with a focus on filling 3,000 new beds and improving execution. Demand remains strong, but policy changes and payer scrutiny present headwinds. Expense management and capital deployment prioritize debt reduction and operational efficiency.
-
Leadership is driving organizational changes to improve execution and facility performance, with a focus on maximizing existing assets and reducing costs. Financial guidance is conservative, prioritizing debt reduction as CapEx declines, while risk management addresses rising malpractice claims and payer challenges.
-
A leading behavioral health provider outlined its focus on patient care, operational excellence, and ramping new bed capacity, with 2026 revenue guidance of $3.37–$3.45 billion and significant CapEx reductions. Quality outcomes and payer relationships are key, while legal expenses are expected to decline.
-
The conference highlighted strong operational progress, significant bed growth, and ongoing investments in quality and technology. Despite 2025 financial headwinds from payer pressure and regulatory changes, the company expects ramping new facilities, reduced CapEx, and enhanced execution to drive EBITDA and free cash flow growth in 2026 and beyond.
Fiscal Year 2025
-
Q4 and full-year 2025 saw solid revenue and EBITDA growth, with expansion through joint ventures and disciplined capital allocation. 2026 guidance anticipates modest volume growth, lower CapEx, and a focus on operational excellence amid regulatory and payer headwinds, especially from New York Medicaid changes.
-
Settled major litigation for $179 million with no admission of wrongdoing, modestly increased leverage, and adjusted 2025 guidance after results came in below expectations. Growth is driven by new bed additions, JV partnerships, and targeted facility closures, with a focus on ramping up earnings in 2026.
-
Q3 2025 revenue grew 4.4% year-over-year, but Adjusted EBITDA declined due to Medicaid volume softness and higher expenses. 2025 guidance was lowered, CapEx is being reduced, and five underperforming facilities were closed to optimize the portfolio.
-
Management outlined a strategic shift with a $300 million CapEx reduction for 2026, targeted facility closures, and a focus on high-demand, high-reimbursement markets. Despite recent volume softness, strong demand, technology investments, and operational discipline are expected to drive EBITDA and free cash flow growth in 2026 and beyond.
-
Q2 2025 revenue rose 9.2% to $869.2M, with Adjusted EBITDA up 7.5% year-over-year. Medicaid volumes were pressured, but commercial and Medicare volumes grew. Guidance was updated for lower volume growth and higher startup costs, offset by increased supplemental payments.
-
Revenue and EBITDA are tracking in line with guidance, with strong demand across all service lines and significant bed expansion planned through 2028. Policy and supplemental payment dynamics are being closely monitored, while pricing growth remains in the low to mid-single digits.
-
Q1 2025 revenue and adjusted EBITDA met or exceeded guidance, with strong bed and CTC expansion. Guidance for 2025 and long-term growth was reaffirmed, despite ongoing legal costs and some underperforming facilities. Demand and labor trends remain favorable.
-
Long-term targets have been recalibrated to balance growth and cash flow, with a focus on de novo facilities and joint ventures. Revenue growth is guided at 8% for 2025, with CTC business moderating to mid-single digits and operational risks from tariffs and wage inflation well managed.
-
Performance was impacted by higher malpractice costs, lower-than-expected bed growth, and timing of new facility openings. CapEx is being moderated, with positive cash flow targeted by end of 2026. Pricing growth is expected to slow as labor costs normalize and supplemental payment tailwinds fade.
-
Behavioral health demand is surging, driving facility and service expansion, with focus on high-acuity care and tech investments. Financial headwinds from liability costs and underperforming sites are addressed via operational improvements and disciplined capital allocation. Opioid clinic growth and acquisition opportunities continue.
-
Behavioral health demand and unmet needs are driving rapid facility and bed expansion, with 1,300 new beds in 2024 and 1,200 more under construction. Investments in quality, technology, and partnerships are supporting operational gains, while capital spending will moderate after 2025 as new capacity ramps up.
Fiscal Year 2024
-
Fourth quarter revenue grew 4.2% year-over-year, with full-year revenue up 7.7%. 2025 guidance anticipates continued growth, but includes headwinds from underperforming facilities, higher liability costs, and conservative rate assumptions. A $300 million share repurchase program was authorized.
-
Strong bipartisan support and robust demand underpin stable funding and expansion plans, despite recent volume moderation linked to local media coverage. Proactive outreach, JV growth, and technology investments support resilience, with CapEx and startup costs peaking in 2025.
-
Q3 2024 saw 8.7% revenue growth and 10.5% Adjusted EBITDA growth, with strong patient day and rate increases. Guidance was revised downward due to temporary volume softness from media scrutiny, but significant bed expansion and favorable labor trends support future growth.
-
Q2 2024 saw 8.8% revenue growth and 7.6% adjusted EBITDA growth year-over-year, with strong demand and ongoing expansion in beds and facilities. Updated 2024 guidance reflects facility closures, while labor and Medicaid rate trends remain stable.